Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
C-19-ACS: Early ACS Therapy for COVID-19 Cardiac Complications
NCT04333407Terminated
- Sponsor
- Imperial College London
- Start
- Apr 2020
- Primary completion
- Nov 2021
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Randomised, open-label trial of aspirin, clopidogrel, rivaroxaban, atorvastatin and omeprazole in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Imperial College London. Primary endpoint: All-cause mortality at 30 days. Started Apr 2020; status: terminated.
02
Drugs
aspirinclopidogrelrivaroxabanatorvastatinomeprazole
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04333407.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04333407.